HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Coleman, W. H. Articles by Donta, S. T. Search for Related Content PubMed PubMed Citation Articles by Coleman, W. H. Articles by Donta, S. T. Agricola Articles by Coleman, W. H. Articles by Donta, S. T.

Inhibition of β-adrenergic binding by fungal metabolites

Department of Biology, University of Hartford, West Hartford, CT 06117, USA

^*Department of Medicine, University of Connecticut School of Medicine, Farmington, CT 06030 and Department of Veterans Affairs, Newington, CT 06111, USA

Received September 26, 1991 Revision received May 28, 1992.
Accepted May 28, 1992

Strains of Aspergillus flavus, Fusarium sp., Rhizopus sp. and Candida albicans all produced inhibitors of β-adrenergic receptor binding; strains of Saccharomyces sp. and Schizosaccharomyces sp. did not. In tests with glutamic acid as the sole nutrient source, a Fusarium sp. produced four-fold larger amounts of inhibitor than the other fungi. The inhibitor from the Fusarium sp. was further purified by lyophilisation and sequential solvent extractinon in chloroform, ethyl acetate and butanol; 60% of the original activity was recovered. The inhibitor had an estimated molecular size of 650 Da, and did not absorb light in the visible or ultraviolet range. When compared with a similar inhibitor from Escherichia coli, the Fusarium sp. inhibitor appeared to be a more potent inhibitor of β-adrenergic and dopaminergic binding to mammalian cells.